Skip to main content
Premium Trial:

Request an Annual Quote

Akoya Biosciences Closes $50M Funding Round

NEW YORK – Akoya Biosciences said today that it has closed a $50 million funding round.

The Menlo Park, California-based company plans to use the proceeds to fund operation and commercial growth as well as development of its Codex and Phenoptics spatial omics platforms.

The financing was led by Piper Jaffray Merchant Banking and included previous investor Telegraph Hill Partners. New investors included Agilent Technologies and Innovatus Capital Partners. It follows a 2018 Series C round that Akoya used to fund the $37 million acquisition of PerkinElmer's Phenoptics portfolio.

"Akoya is transforming how immunotherapies are developed, from discovery of novel biomarkers in the tumor microenvironment, to deploying high-throughput, highly sensitive information to direct patient therapies." Thomas Schnettler, managing director at Piper Jaffray, said in a statement. "Our investment represents our confidence in Akoya's relentless execution to deliver the next generation of pathology tools."

Schnettler has also joined Akoya's board of directors.

Akoya's platforms allow for multiplexed imaging of protein markers at the single-cell level.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.